VANCOUVER, BC, July 14, 2025 /PRNewswire/ - Galiano Gold Inc. ("Galiano" or the "Company") (TSX: GAU) (NYSE American: GAU) today announced positive results from a deep...
VANCOUVER, BC, July 14, 2025 /CNW/ - Galiano Gold Inc. ("Galiano" or the "Company") (TSX: GAU) (NYSE American: GAU) today announced positive results from a deep...
Minuit Discovery – A Newly Discovered Gold Zone located 75 m north of historical Donchester MineDUP25-059 returns 2.25 g/t Au over 12.8 m, including...
Minuit Discovery – A Newly Discovered Gold Zone located 75 m north of historical Donchester MineDUP25-059 returns 2.25 g/t Au over 12.8 m, including...
High-grade gold, copper, silver and tungsten assay results have been received for the further six holes from the shallow drilling program designed to outline...
High-grade gold, copper, silver and tungsten assay results have been received for the further six holes from the shallow drilling program designed to outline...
ARLINGTON, Va., July 10, 2025 /PRNewswire/ -- Kalorama Information, a leading healthcare market intelligence firm, has published a comprehensive new report, Global Immunoassay Market:...
New York, N.Y., July 10, 2025 (GLOBE NEWSWIRE) -- NANO Nuclear Energy Inc. (NASDAQ: NNE) (“NANO Nuclear” or “the Company”), a leading advanced nuclear energy and technology company focused on developing clean energy solutions, today announced that Chief Executive Officer James Walker will participate in a fireside chat at H.C. Wainwright’s Powering the Future: Advancing Innovation Through Nuclear Virtual Conference hosted by Sameer Joshi, Senior Cleantech Analyst at H.C. Wainwright, on July 15, 2025 at 9:00 a.m., Eastern time.
NEWTON, Mass., July 10, 2025 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets soluble amyloid beta oligomers (AβOs) for the treatment of Alzheimer’s disease (AD), will present new findings at the upcoming Alzheimer's Association International Conference (AAIC®) 2025 in Toronto. The presentations include a cost savings analysis of the use of pTau217 as a screening tool in Acumen’s Phase 2 ALTITUDE-AD trial of sabirnetug as well as a nonclinical study evaluating the relative selectivity of sabirnetug to targeting AβOs versus Aβ monomers. The conference will be held July 27-31, 2025, both in-person and online.
Exploration Drilling Returns High-Grade: 97.9 g/t Au over 1.5 Metres
MONTREAL, July 9, 2025 /CNW/ - VIOR INC. ("Vior" or the "Corporation") (TSXV: VIO) (OTCQB:...
ROUYN-NORANDA, QC, July 9, 2025 /CNW/ - Comet Lithium Corporation (TSXV: CLIC) (FSE: 8QY) ("Comet Lithium" or the "Corporation") is pleased to announce the...